Skip to main content

Table 4 HR (95% CI) of stratified analysis across tertiles of serum betaine levels

From: Serum choline is associated with hepatocellular carcinoma survival: a prospective cohort study

 Liver cancer-specific survivalOverall survival 
T1T2T3P-trendP-interactionT1T2T3P-trendP-interaction
Sexa, b    0.229    0.328
 Men1.000.95 (0.70–1.29)0.73 (0.53–0.99)0.046 1.000.94 (0.70–1.27)0.76 (0.56–1.03)0.078 
 Women1.000.91 (0.30–2.74)1.30 (0.45–3.74)0.590 1.000.83 (0.31–2.24)1.36 (0.53–3.47)0.504 
Agea, b, years    0.627    0.721
  < 601.001.01 (0.72–1.43)0.88 (0.62–1.25)0.460 1.001.01 (0.73–1.41)0.89 (0.64–1.25)0.505 
  ≥ 601.001.17 (0.65–2.13)0.86 (0.47–1.58)0.586 1.001.19 (0.67–2.14)0.90 (0.50–1.62)0.678 
BMIa, b, kg/m2    0.702    0.574
  < 25.01.001.01 (0.73–1.39)0.85 (0.61–1.18)0.331 1.000.96 (0.70–1.32)0.84 (0.62–1.15)0.276 
  ≥ 25.01.002.06 (0.89–4.75)1.78 (0.76–4.15)0.218 1.001.90 (0.87–4.15)1.37 (0.61–3.07)0.526 
Smoking statusa, b    0.097    0.050
 Smoker1.001.16 (0.81–1.68)0.76 (0.52–1.11)0.153 1.001.13 (0.79–1.61)0.79 (0.55–1.13)0.187 
 Non-smoker1.000.90 (0.54–1.50)1.04 (0.64–1.69)0.884 1.000.89 (0.54–1.46)1.05 (0.65–1.69)0.837 
Drinking statusa, b    0.176    0.227
 Drinker1.000.96 (0.61–1.51)0.98 (0.62–1.54)0.932 1.000.97 (0.62–1.52)0.98 (0.63–1.52)0.935 
 Non-Drinker1.000.99 (0.67–1.46)0.78 (0.52–1.17)0.226 1.000.97 (0.66–1.41)0.77 (0.52–1.13)0.187 
AFP levela, b, ng/mL    0.527    0.194
  ≥ 4001.001.03 (0.69–1.54)0.96 (0.63–1.45)0.853 1.000.94 (0.64–1.38)0.93 (0.63–1.38)0.703 
  < 4001.001.25 (0.81–1.95)0.87 (0.55–1.37)0.609 1.001.28 (0.83–1.99)0.98 (0.63–1.52)0.832 
CRP levela, b, mg/L    0.329    0.379
  ≥ 3.01.000.87 (0.61–1.23)0.87 (0.61–1.24)0.446 1.000.83 (0.59–1.17)0.89 (0.63–1.24)0.504 
  < 3.01.001.34 (0.78–2.31)0.70 (0.38–1.31)0.287 1.001.39 (0.82–2.35)0.81 (0.45–1.46)0.525 
Serum folate levela, b    0.250    0.387
 High1.001.27 (0.82–1.96)0.86 (0.54–1.37)0.545 1.001.17 (0.77–1.78)0.91 (0.59–1.41)0.674 
 Low1.001.03 (0.68–1.54)0.92 (0.62–1.38)0.695 1.001.01 (0.68–1.51)0.93 (0.63–1.37)0.700 
Liver damage levela, b    0.145    0.313
 11.001.66 (0.50–5.49)0.63 (0.14–2.86)0.536 1.001.19 (0.40–3.55)0.60 (0.17–2.14)0.396 
 21.001.46 (0.87–2.45)1.11 (0.66–1.89)0.716 1.001.47 (0.88–2.47)1.24 (0.74–2.09)0.430 
  ≥ 31.000.83 (0.56–1.24)0.84 (0.57–1.24)0.398 1.000.84 (0.57–1.23)0.84 (0.58–1.22)0.361 
Presence of fatty livera, b    0.664    0.333
 Yes1.001.39 (0.46–4.19)1.49 (0.53–4.20)0.461 1.001.56 (0.57–4.24)1.76 (0.69–4.51)0.245 
 No1.001.04 (0.77–1.42)0.81 (0.59–1.11)0.194 1.001.03 (0.76–1.39)0.83 (0.61–1.12)0.225 
Presence of cirrhosisa, b    0.136    0.069
 Yes1.001.28 (0.85–1.95)0.89 (0.59–1.35)0.552 1.001.27 (0.85–1.91)0.95 (0.64–1.40)0.732 
 No1.001.04 (0.67–1.60)0.76 (0.48–1.19)0.164 1.000.87 (0.57–1.35)0.71 (0.46–1.10)0.118 
BCLC stagea, b    0.653    0.632
 0/A1.001.51 (0.69–3.27)1.06 (0.46–2.46)0.900 1.001.63 (0.76–3.50)1.11 (0.52–2.40)0.822 
 B/C1.000.94 (0.66–1.33)0.84 (0.59–1.19)0.325 1.000.91 (0.65–1.28)0.87 (0.62–1.21)0.405 
Treatmenta, b    0.292    0.305
 Liver resection1.001.24 (0.67–2.30)1.02 (0.53–1.98)0.945 1.001.14 (0.64–2.03)0.88 (0.48–1.64)0.720 
 Intervention1.000.82 (0.57–1.17)0.67 (0.46–0.97)0.032 1.000.82 (0.58–1.17)0.72 (0.50–1.02)0.065 
 Others1.001.41 (0.57–3.48)0.84 (0.32–2.20)0.668 1.001.47 (0.60–3.64)1.03 (0.41–2.59)0.974 
  1. a Covariates adjusted for age, sex, BMI, education level, smoking status, baseline liver damage level, BCLC stage, treatment, AFP level and CRP level
  2. b Stratified factors were not included in the corresponding models